Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Restore CFTR FunctionEnrolling Location: Multiple care centres across the US & NSW, Australia
Study of VX-445 triple combination in children 6-11 years old with cystic fibrosis , protocol number NCT03691779 VX18-445-106
This study will look at the safety and effectiveness of three CFTR modulators when taken in combination: VX-445 (elexacaftor), tezacaftor and ivacaftor. CFTR modulators are drugs intended to help CFTR protein function closer to normal.
Age:
6 Years to 11 Years
Mutation(s):
Two Copies F508del or One Copy F508del
FEV1% Predicted:
40% or greater
Number of Visits:
9
Length of Participation:
32
Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US & Australia
Phase 1/2 Study of VX-445 combination drug in healthy adults and then in people with cystic fibrosis. , protocol number NCT03227471 VX16-445-001
This study is taking place at multiple care centres across the US and Australia. It will look at the safety and effectiveness of the drug VX-445.
18 years and older
No mutation requirement
40-90%
6
12 weeks
Restore CFTR FunctionClosed to enrollment Location: Australia
A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation , protocol number NCT02875366 VX15-809-112
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
>12 years
Homozygous F508del
FEV1 at least 40% and not greater than 90% of predicted.
Not specified
Not Specified
OtherActive, not recruiting Location: Australia, Melbourne
CPET in CF patients with one G551D mutation taking VX770 , protocol number NCT01937325
Double-blind, placebo-controlled cross-over study of 20 patients currently awaiting initiation of ivacaftor therapy.
16-70 years
Hetrozygous G551D
> 25%
224 days
ObservationalEnrolling Location: Australia, Melbourne
The Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-oesophageal Function , protocol number NCT00164021 NCT00164021
A factorial longitudinal study will be undertaken in adults with cystic fibrosis. Results will be compared with age matched healthy controls. It is not deemed appropriate to randomise patients with gastro-oesophageal reflux(GOR) to a treatment versus no treatment group as immediate treatment for GOR once diagnosed is regarded as obligatory. Subjects: 180 adults with CF will be recruited from the Adult Cystic Fibrosis Unit at the Alfred Hospital to participate in the study. The ambulatory studies will be undertaken during baseline state in the outpatient setting. Fifteen age matched control subjects will be recruited from the general population.
OtherEnrolling Location: Australia - VIC
The Alfred Step Test Exercise Protocols (A-STEP and A-STEPmax): Developed for Adults With Cystic Fibrosis (A-STEP/max) , protocol number NCT02717650
Feasibility and Validation of the Alfred Step Test Exercise Protocols (A-STEP and A-STEPmax): Developed to Assess Exercise Tolerance and Determine Maximum Oxygen Uptake in Adults With Cystic Fibrosis Across the Disease Spectrum
>18 years
FEV1 greater than 20%
Restore CFTR FunctionEnrolling Location: Australia
A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation , protocol number NCT02742519 VX15-770-123
A Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long-term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
3-5 years
Restore CFTR FunctionCompleted with results Location: LOCATION: Perth Linear Clinical Research, Contact: Jennifer Seabourne CONTACT: [email protected] Brisbane-Q-pharm CONTACT: Sharon Rankine Phone: 0439 664 900,; Email: [email protected]
A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants , protocol number NCT03173573 FDL176-2016-01
This is a 5-part study. Part 1 is a double blind, placebo-controlled, dose escalation, first-in-human study to assess the safety, tolerability and PK profiles following single oral administration of FDL176 to healthy male participants. Part 2 is a single dose, open-label study in healthy male participants to determine the effect of food on the PK profile of FDL176. Part 3 is a single dose, double blind, placebo-controlled study in healthy female participants to assess the PK, safety and tolerability profiles of FDL176. Part 4 is a randomised, double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability and PK profiles following multiple oral administrations of FDL176 to healthy male and female participants. Part 5 is a single dose, open-label study in male and female participants with CF to determine the PK profile of FDL176.
18 Years to 55 Years
Restore CFTR FunctionEnrolling Location: Australia - QLD
A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects , protocol number NCT03093714 FDL169-2015-04
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation
18 Years to 85 Years
Homozygous for the F508del-CFTR mutation.
(FEV1) >40% of predicted normal for age, sex and height.
Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (SAPHIRA1) , protocol number NCT02707562
A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation
G551D
Pre- or post-bronchodilator FEV1 ≥ 40% of predicted normal